2005
DOI: 10.1016/s1359-6446(04)03333-1
|View full text |Cite
|
Sign up to set email alerts
|

Transferrin: structure, function and potential therapeutic actions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
275
0
16

Year Published

2010
2010
2017
2017

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 384 publications
(293 citation statements)
references
References 72 publications
2
275
0
16
Order By: Relevance
“…It is a powerful chelator, capable of binding iron tightly but reversibly. A molecule of transferrin can bind two atoms of ferric iron (Fe 3+ ) with high affinity, which is higher in the extracellular pH of 7.4 and decreases in acidified endosomes, allowing the dissociation of Fe 3+ (Gomme and McCann 2005). The primary role of transferrin is to transport iron safely around the body to supply growing cells (Huebers and Finch 1987).…”
Section: Transferrinmentioning
confidence: 99%
“…It is a powerful chelator, capable of binding iron tightly but reversibly. A molecule of transferrin can bind two atoms of ferric iron (Fe 3+ ) with high affinity, which is higher in the extracellular pH of 7.4 and decreases in acidified endosomes, allowing the dissociation of Fe 3+ (Gomme and McCann 2005). The primary role of transferrin is to transport iron safely around the body to supply growing cells (Huebers and Finch 1987).…”
Section: Transferrinmentioning
confidence: 99%
“…-create binding pocket [73]. Gly65, Glu83, Tyr85, Arg124, Lys206, Ser248, Lys296 -they stabilize metal binding site and play crucial role in iron release [73].…”
Section: Methodsmentioning
confidence: 99%
“…All identified sites were situated on the protein surface, with site 3 forming a kind of shallow nest. Transferrin The most plausible binding pocket observed for transferrin is placed in a functionally important area of this protein including Asn413 and Asn611 [73] and it was identified as site 1. The second binding site was the target of 20% of the ligand population.…”
Section: Binding Sites Analysismentioning
confidence: 99%
“…For these studies we utilised an siRNA sequence for knockdown of luciferase in bioluminescent xenograft models, and transferrin as the ligand for cancer cell targeting. The receptor for transferrin is expressed on proliferating cells 22 and has been used for delivery of a range of therapeutic agents 23 to cancer cells, including siRNA. 24 Incorporation of transferrin-conjugated PEI into complexes has also been shown to improve DNA delivery to tumour cells; 25,26 the mechanism may involve shielding the positive charge on PEI-DNA complexes in vivo, reducing accumulation in 'first pass' organs and enabling them to reach the target tissues including tumours.…”
Section: -21mentioning
confidence: 99%